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Abstract: In earlier studies, we generated concentration-response (E/c) curves with CPA (N6-
cyclopentyladenosine; a selective A1 adenosine receptor agonist) and adenosine, in the presence or 
absence of S-(2-hydroxy-5-nitrobenzyl)-6-thioinosine (NBTI, a selective nucleoside transport 
inhibitor), and with or without a pretreatment with 8-cyclopentyl-N3-[3-(4-(fluorosulfonyl)-
benzoyloxy)propyl]-N1-propylxanthine (FSCPX, a chemical known as a selective, irreversible A1 
adenosine receptor antagonist), in isolated, paced guinea pig left atria. Meanwhile, we observed a 
paradoxical phenomenon, i.e. the co-treatment with FSCPX and NBTI appeared to enhance the 
direct negative inotropic response to adenosine. In the present in silico study, we aimed to 
reproduce eight of these E/c curves. Four models (and two additional variants of the last model) 
were constructed, each one representing a set of assumptions, in order to find the model exhibiting 
the best fit to the ex vivo data, and to gain insight into the paradoxical phenomenon in question. We 
have obtained in silico evidence for an interference between effects of FSCPX and NBTI upon our 
ex vivo experimental setting. Regarding the mechanism of this interference, in silico evidence has 
been gained for the assumption that FSCPX inhibits the effect of NBTI on the level of endogenous 
(but not exogenous) adenosine. As an explanation, it may be hypothesized that FSCPX inhibits an 
enzyme participating in the interstitial adenosine formation. In addition, our results suggest that 
NBTI does not stop the inward adenosine flux in the guinea pig atrium completely. 
Keywords: adenosine; CPA; FSCPX; NBTI; A1 adenosine receptor; operational model of agonism; 
receptorial responsiveness method; RRM; computer simulation 
 
1. Introduction 
The A1 adenosine receptor, a member of the adenosine receptor family (formerly known as P1 
purinoceptors), exerts extensive regulatory (mainly protective and regenerative) functions in almost 
all tissues [1,2], including the myocardium [3]. As a protective action, the A1 adenosine receptor 
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mediates strong negative inotropic effect consisting of an indirect component (decreasing the 
stimulated contractile force, seen in both the atrium and ventricle) and a direct one (reducing the 
resting contractile force, only characteristic of the atrium in most species) [4]. 
In earlier ex vivo studies [5,6] carried out in isolated, paced guinea pig left atria (a simple and 
reliable model to investigate the myocardial adenosinergic system), we observed a paradoxical 
phenomenon concerning FSCPX, a chemical widely known and used as a selective, irreversible A1 
adenosine receptor antagonist [7–10]. Namely, in the presence of NBTI, a selective and potent 
inhibitor of the nucleoside transporter type ENT1 (the main carrier for the myocardial adenosine 
transport) [11,12], FSCPX pretreatment appeared to enhance the maximal response to adenosine, the 
physiological full agonist for the A1 adenosine receptor. Back then, we considered this phenomenon 
as a misleading plotting peculiarity that was caused by neglecting the effect evoked by the surplus 
endogenous adenosine accumulated due to NBTI in the cardiac interstitium [5]. 
In a subsequent study [13], we in silico reconstructed some concentration-response (E/c) curves 
selected from [6]. Based on the behavior of the simulated E/c curves of different adenosine receptor 
agonists, we have hypothesized that pretreatment with FSCPX alters the influence of NBTI on the E/c 
curves. As a mechanism, we have assumed that FSCPX may modify ENT1 (the equilibrative and 
NBTI-sensitive nucleoside transporter [11,12]) in a way that ENT1 preserves its ability to transport 
adenosine but NBTI can less inhibit this transport [13]. 
  
Figure 1. Concentration-response (E/c) curves of CPA, a synthetic full agonist of the A1 adenosine 
receptor (having relatively long half-life, see: [15]), and adenosine, the physiological adenosine 
receptor full agonist (possessing very short half-life, see: [15]), where the direct negative inotropic 
response of isolated, paced guinea pig left atria were measured. The E/c curves illustrate the influence 
of NBTI, a nucleoside transport inhibitor, on the effect of CPA and adenosine, without (blue curves) 
and with (red curves) a pretreatment with FSCPX, a chemical known as an irreversible A1 adenosine 
receptor antagonist. The x-axis shows the common logarithm of the molar concentration of the given 
agonist (in the bathing medium), while the y-axis denotes the direct negative inotropic effect 
(determined as a percentage decrease of the initial contractile force). The symbols show the averaged 
responses (± SEM), and the lines represent the fitted Hill equation. CPA: N6-cyclopentyladenosine; 
Ado: adenosine; NBTI: S-(2-hydroxy-5-nitrobenzyl)-6-thioinosine; FSCPX: 8-cyclopentyl-N3-[3-(4-
(fluorosulfonyl)benzoyloxy)propyl]-N1-propylxanthine. Data are redrawn from [14]. 
Next, we tested this putative effect of FSCPX in the isolated, paced guinea pig left atrium [14]. 
Based on results of that study (Fig. 1), we have propounded a new hypothesis, i.e. FSCPX 
pretreatment inhibits only one effect of NBTI on the E/c curves of adenosine receptor agonists, the 
one that is mediated via increasing the interstitial concentration of endogenous adenosine. The other 
effect of NBTI is mediated by elevating the interstitial level of exogenous adenosine (if any), and that 
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action is proposed to remain intact after an FSCPX pretreatment. As a mechanism for this 
phenomenon, we have supposed that FSCPX may inhibit one (or some) enzyme(s) participating in 
the interstitial formation of adenosine [14], an action not acknowledged thus far. 
Addressing the strict distinction between endogenous and exogenous adenosine cannot be 
overemphasized given that in our experimental conditions, elevation in the interstitial level of 
endogenous versus exogenous adenosine exerts the opposite effect on the E/c curve of adenosine 
[5,6]. In general, NBTI, by blunting the normally inward transmembranous adenosine flux in the 
heart and thereby preventing adenosine from the intracellular elimination [16–18], increases the 
interstitial level of adenosine of both origins. However, endogenous adenosine is accumulated by 
NBTI before the generation of the E/c curve, thus it consumes (in part) the response capacity of the 
A1 receptors and thereby decreases the observable effect evoked later by an exogenous agonist (used 
for the E/c curve). In contrast, exogenous adenosine is accumulated by NBTI during the construction 
of the E/c curve, so it can elicit a greater effect. A distinction between effects of endogenous and 
exogenous agonists (in experimental arrangements such as the present one) forms the basis for the 
so-called receptorial responsiveness method (RRM) [19,20], theoretical concept of which was used for 
the current work too. It is also important that CPA, a synthetic A1 adenosine receptor full agonist, is 
relatively resistant to the adenosine-handling enzymes [15], so its level is minimally affected by NBTI. 
The goal of the present study was to revisit the issue of the above-mentioned paradoxical 
phenomenon, and to in silico reevaluate the major conclusions of our relevant ex vivo [5,14] and in 
silico [13] investigations. For this purpose, eight (averaged) E/c curves, based on which these 
conclusions were drawn, were selected (Figure 1, Table 1) and reproduced in silico herein. Simulation 
was made using different assumptions, and then the different models were compared. 
Table 1. The Hill parameters of the CPA and adenosine concentration-response (E/c) curves of Fig. 1. 
CPA Control FSCPX NBTI FSCPX+NBTI 
Emax 89.21 ± 1.46 87.49 ± 1.75 71.68 ± 5.24 84.6 ± 1.64 
logEC50 −7.47 ± 0.074 −6.85 ± 0.05 −6.53 ± 0.32 −6.86 ± 0.06 
n 0.98 ± 0.03 0.93 ± 0.04 0.84 ± 0.09 0.86 ± 0.02 
Ado Control FSCPX NBTI FSCPX+NBTI 
Emax 91.04 ± 1 93.85 ± 1.78 71.23 ± 4.9  90.22 ± 1 
logEC50 −4.74 ± 0.13 −3.88 ± 0.07 −5.92 ± 0.25  −6.08 ± 0.07 
n 0.85 ± 0.03 0.83 ± 0.07 0.81 ± 0.13 0.83 ± 0.1 
Emax, logEC50 and n (mean ± SEM) are best-fit values of the Hill equation fitted to the individual E/c 
curves. SEM: standard error of the mean (for more detail, see: Fig. 1). Data are from [14]. 
2. Results 
2.1. Models 1 and 2 
In Models 1 and 2 (which differ from each other in their Em parameter, 100 and 99, respectively), 
the simplest conditions were assumed to simulate the guinea pig atrial adenosine homeostasis and 
A1 adenosinergic control of contractility. A complete blockade of the transport of agonist A 
(representing adenosine) in response of agent NB (representing NBTI) was supposed with no 
interaction between effects of agent X (symbolizing FSCPX) and agent NB. While the simple E/c 
curves (i.e. curves without any agent NB treatment; see subsection 4.3.) could be simulated well, the 
complex E/c curves (receiving an NB treatment; see subsection 4.4.) considerably differed from the 
original ex vivo E/c curves (seen in Figure 1), regarding their positions and, for the X+NB co-treated 
E/c curves, their shapes too (Figure 2). Thus, neither Model 1 nor Model 2 were suitable to properly 
model the biological system (represented by Figure 1 and Table 1). 
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Figure 2. Simulated concentration-response (E/c) curves of agonist C (representing CPA, a synthetic 
A1 adenosine receptor agonist with long half-life) and agonist A (symbolizing adenosine, the 
physiological adenosine receptor agonist with short half-life), according to Models 1 and 2 (modelling 
the supraventricular myocardium, where A1 adenosine receptor agonists exert strong direct negative 
inotropic effect). The only difference between Model 1 and Model 2 is the value of the Em parameter 
(100 and 99, respectively, see Equations (1) and (2)). The E/c curves show the influence of agent NB 
(representing NBTI, a nucleoside transport inhibitor) on the effect evoked by agonist C and A, without 
(blue curves) and with (red curves) a pretreatment with agent X (representative of FSCPX, a chemical 
known as an irreversible A1 adenosine receptor antagonist). The x-axis denotes the common logarithm 
of the molar concentration of the given agonist (in the organ bath), and the y-axis shows the effect. 
The lines represent the fitted Hill equation (see Equation (4)). CPA: N6-cyclopentyladenosine; FSCPX: 
8-cyclopentyl-N3-[3-(4-(fluorosulfonyl)benzoyloxy)propyl]-N1-propylxanthine; NBTI: S-(2-hydroxy-
5-nitrobenzyl)-6-thioinosine. 
The main conclusion drawn from these two early models is that Em, a parameter of the 
operational model defining the maximal signal amplification ability of the system, has a profound 
impact on the behavior of our complex E/c curves. Namely, if Em was 100 (more precisely, if Em was 
in an interval of 100–≈99.9), both solely NB-treated E/c curves exceeded the corresponding X+NB co-
treated E/c curves (irrespectively of the exogenous agonist used). In turn, if Em was below this value 
(in fact, below the above-mentioned value range), the X+NB co-treated E/c curves surpassed the 
corresponding NB-treated E/c curves (Figure 2).  
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At about Em = 99.9, the corresponding complex E/c curves practically coincided (data not shown). 
This observation approximated the lower limit of the range for Em (100–≈99.9), in which the 
paradoxical phenomenon (i.e. FSCPX seemingly increases the response to adenosine) did not occur. 
It should be noted that Em values higher than 100 do not have biological meaning in the ex vivo 
system to be simulated. Accordingly, raising Em above 100 led to, first, enormously high, then 
negative Emax values for the complex E/c curves (data not shown). 
  
  
Figure 3. Simulated concentration-response (E/c) curves of agonist C (representing CPA, a synthetic 
A1 adenosine receptor agonist with long half-life) and agonist A (symbolizing adenosine, the 
physiological adenosine receptor agonist with short half-life), according to Models 3 and 4 (modelling 
the supraventricular myocardium, where A1 adenosine receptor agonists exert strong direct negative 
inotropic effect). The E/c curves show the influence of agent NB (representing NBTI, a nucleoside 
transport inhibitor) on the effect evoked by agonist C and A, without (blue curves) and with (red 
curves) a pretreatment with agent X (representative of FSCPX, a chemical known as an irreversible 
A1 adenosine receptor antagonist). The x-axis denotes the common logarithm of the molar 
concentration of the given agonist (in the organ bath), and the y-axis indicates the effect. The lines 
represent the fitted Hill equation (see: Equation (4)). CPA: N6-cyclopentyladenosine; FSCPX: 8-
cyclopentyl-N3-[3-(4-(fluorosulfonyl)benzoyloxy)propyl]-N1-propylxanthine; NBTI: S-(2-hydroxy-5-
nitrobenzyl)-6-thioinosine. 
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2.2. Model 3 
Model 3 differed from the earlier ones regarding three properties: (1) Em was set to 90, (2) cbias 
(see: Equation (2) in the 4.4. subsection) was set to a cx value measured previously in the original ex 
vivo system (in the case of the sole NBTI treatment) [14], and (3) a slow agonist A transport was 
supposed under the effect of agent NB (instead of the total stop seen in Models 1 and 2, furthermore 
in Model 4-v1 below). Model 3 acceptably simulated all simple E/c curves and the solely NB-treated 
E/c curves. However, both X+NB co-treated E/c curves showed substantial deviation from the 
corresponding ex vivo E/c curves seen in Fig. 1 (Fig. 3). Thus, an interference should be assumed 
between effects of agents X and NB. 
2.3. Model 4 
Model 4 only differed from Model 3 in that it considered the effect of agent NB on the level of 
the endogenous agonist A with two distinct cbias values (both obtained from [14]), separately for the 
pure NB treatment and the X+NB co-treatment (assuming an interaction between agents X and NB). 
The fact that cbias for the X+NB co-treatment was smaller than that for the sole NB-treatment modelled 
that agent X inhibited the action of agent NB to increase the concentration of the endogenous (but not 
exogenous) agonist A. Contrary to the previous models, Model 4 adequately simulated all E/c curves 
(cf. Figure 3 and Table 2 with Figure 1 and Table 1, respectively). It is also important to note that 
moderate changes of values (in both directions) of the model parameters did not cause dramatic 
changes in the E/c curves (contrary to that was experienced in the case of Em close to 100). 
Table 2. The Hill parameters of the concentration-response (E/c) curves that were simulated according 
to the Model 4 and are presented in Fig. 3. 
C Co X NB X+NB 
Emax 89.61 ± 0.03 88.45 ± 0.07 70.67 ± 0.12 87.27 ± 0.12 
logEC50 −7.53 ± 0.001 −6.8 ± 0.003 −6.66 ± 0.005 −6.71 ± 0.005 
n 0.75 ± 0.001 0.76 ± 0.003 0.91 ± 0.008 0.82 ± 0.006 
A Co X NB X+NB 
Emax 89.76 ± 0.01 89 ± 0.04 70.61 ± 0.14 87.27 ± 0.15 
logEC50 −4.92 ± 0.0003 −4.19 ± 0.0008 −5.88 ± 0.005 −5.93 ± 0.005 
n 0.75 ± 0.0004 0.75 ± 0.0007 0.91 ± 0.009 0.82 ± 0.006 
Emax, logEC50 and n (mean ± SE) are best-fit values of the Hill equation (Equation (4)) fitted to the 
simulated E/c curves. SE (standard error) characterizes how precisely the given best-fit value has been 
determined (for more detail, see: Fig. 3). 
2.4. Models 4-v1 and 4-v2 
Model 4-v1 and Model 4-v2, variants of Model 4, modified only the complex E/c curves of 
agonist A and the X+NB co-treated E/c curve of agonist A, respectively, in comparison with Model 4. 
Model 4-v1 differed from Model 4 in assuming the complete inhibition of the agonist A transport 
by agent NB (again). The E/c curves of agonist A subjected to any agent NT treatment showed less 
similarity to the ex vivo counterparts than the corresponding curves in Model 4 did, regarding their 
position (cf. Figure 3 and Figure 4 with Figure 1). Consequently, in our in silico system, a weak agonist 
A transport should be assumed in the presence of agent NB, as shown by Model 4. 
In turn, Model 4-v2 differed from Model 4 in supposing that a pretreatment with agent X 
inhibited both actions of agent NB (i.e. the increase of levels of both endogenous and exogenous 
agonist A). Accordingly, in Model 4-v2, in addition to the use of two cbias values, a weakened 
inhibition by NB on the agonist A transport after the agent X pretreatment was considered as 
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compared to the solely NB-treated state (modelling that agent X blunted the action of agent NB on 
the level of exogenous agonist A). This resulted in a dislocation of the X+NB co-treated E/c curve of 
agonist A as compared to the corresponding curve in Model 4 as well as in the original ex vivo system 
(cf. Figure 4 with Figure 3 and Figure 1). Consistent with this, any decrease in the extent of the 
supposed influence of agent X on the level of the exogenous agonist A ameliorated the position of 
the X+NB co-treated E/c curve of agonist A (data not shown). Thus, Model 4-v2 also yielded a worse 
outcome than Model 4. 
Taking all together, Model 4 conferred the best similarity to the original ex vivo E/c curves 
(presented in Figure 1), so Model 4 has been regarded the final model of the present work. 
  
Figure 4. Simulated concentration-response (E/c) curves of agonist A (representing adenosine, the 
physiological adenosine receptor agonist with short half-life), according to Models 4-v1 and 4-v2 
(modelling the atrial myocardium, where A1 adenosine receptor agonists evoke strong direct negative 
inotropy). The E/c curves denote the influence of agent NB (modelling NBTI, a nucleoside transport 
inhibitor) on the effect of agonist A, without (blue curves) and with (red curves) a pretreatment with 
agent X (representing FSCPX, a chemical known as an irreversible A1 adenosine receptor antagonist). 
The x-axis shows the common logarithm of the molar concentration of agonist A (in the organ bath), 
and the y-axis denotes the effect. The lines represent the fitted Hill equation (see: Equation (4)). 
FSCPX: 8-cyclopentyl-N3-[3-(4-(fluorosulfonyl)benzoyloxy)propyl]-N1-propylxanthine; NBTI: S-(2-
hydroxy-5-nitrobenzyl)-6-thioinosine. 
3. Discussion 
In the present in silico study, we have found that Em parameter of the operational model of 
agonism [21] can influence the behavior of our complex E/c curves (reflecting the net of actions of 
two agonists while not accounting for one of them), i.e. the rank order of curves regarding the 
maximal response can be changed, an effect not characteristic of our simple E/c curves (expressing 
the action of one agonist in a standard way). Furthermore, we have gained in silico evidence for an 
interference between effects of FSCPX and NBTI in our ex vivo experimental setting used in several 
earlier studies [5,6,14]. This finding extends beyond the well-established A1 adenosine receptor 
antagonist property of FSCPX, indicating an inhibitory action exerted by FSCPX on the interstitial 
adenosine accumulation produced by NBTI, a selective and potent blocker of the nucleoside 
transporter type ENT1. Regarding the mechanism of this interference, in silico evidence has been 
obtained supporting that FSCPX only inhibits the interstitial accumulation of endogenous (but not 
exogenous) adenosine. As an additional result, we have found that NBTI seems not to completely 
inhibit the inward adenosine flux in the guinea pig atrium. 
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Cardiac functions may be modelled using various approaches, including in silico [22,23], ex vivo 
[24] and in vivo [25] works. The present investigation was designed to simulate the main adenosine-
handling mechanisms and the A1 adenosinergic control of contractility in the guinea pig left atrial 
myocardium, similarly to our recent in silico study [13]. We have in silico reproduced eight E/c curves 
that were generated with CPA and adenosine in our recent ex vivo study [14]. During this procedure, 
four models (and two additional variants of the last one) were constructed, each one addressing a set 
of assumptions, in order to find the final model exhibiting the best fit to the ex vivo results (seen in 
Figure 1). 
In light of the new findings, some conclusions of our previous in silico study [13] should be 
refined. In several earlier investigations carried out in our laboratory, a paradoxical appearance of 
the FSCPX+NBTI co-treated adenosine E/c curve relative to the FSCPX-naïve NBTI-treated adenosine 
E/c curve was observed, namely the irreversible antagonist FSCPX seemed to increase the maximal 
response of the adenosine E/c curve in the presence of NBTI, a nucleoside transport blocker [5,6,14]. 
In [13], this phenomenon could be in silico reproduced by supposing that FSCPX diminishes the 
effects of NBTI on the level of both endogenous and exogenous adenosine. Putting this earlier result 
into a biological context, this may indicate that FSCPX modifies ENT1 in a way that the altered ENT1 
can carry adenosine well, but it can be less inhibited by NBTI. In the present work, however, the 
paradoxical phenomenon in question could be reproduced in an alternative way as well, namely by 
decreasing the Em parameter of the operational model of agonism (as shown by Models 1 and 2 in 
Figure 2). Thus, the paradoxical appearance of the FSCPX+NBTI co-treated and only NBTI-treated 
adenosine E/c curves may indicate, but does not evidence, an interference between effects of FSCPX 
and NBTI. Nonetheless, an important conclusion of [13], i.e. it is necessary to construct an ex vivo 
FSCPX+NBTI co-treated CPA E/c curve in order to clarify whether the above-mentioned interference 
exists, proved to be useful. Owing to the improved experimental protocols used in [14], it has been 
demonstrated that FSCPX considerably reduces the interstitial accumulation of endogenous 
adenosine caused by NBTI, providing ex vivo evidence of the interaction between FSCPX and NBTI 
at the level of their effects. 
In the operational model of agonism, a widely known quantitative model of receptor function, 
Em represents the maximum of the transducer function (signal amplification) of the receptor system 
(consisting of a receptor together with its postreceptorial signaling), hence it indicates the achievable 
maximal effect in the given system [21,26]. In the present investigation, the unexpectedly great impact 
of whether Em was set to 100 (or to a value very close to 100) or not may be associated with the fact 
that Em = 100 is an absolute maximum for the present system. This is because effect values of our 
original ex vivo E/c curves (that were obtained from [14] and were simulated herein) had been 
defined as a percentage decrease of the initial contractile force, and the contractile force cannot be 
less than zero. 
It should be noted that the operational model has been recently criticized for its some 
unfavorable features during curve fitting and for some conceptional deficiencies that make the 
interpretation of results problematic in some cases [26,27]. However, owing to its comprehensive and 
relatively flexible nature [21,26], and to the fact that it has an extended version capable of handling 
the co-action of two agonists in the same system [28], the operational model is suitable to serve as a 
framework for computer simulation where it is used to generate E/c curves. 
Keeping the pivotal role of Em in the simulation of our complex E/c curves in mind, further in 
silico models were evaluated: (1) Model 3 for the scenario that there is no interaction between FSCPX 
and NBTI, (2) Model 4 to represent that there is an interaction that affects only the fate of the 
endogenous agonist A (symbolizing adenosine produced in the myocardial interstitium), and (3) 
Model 4-v2 to represent the existence of such an interaction that affects the fate of both endogenous 
and exogenous agonist A (this latter one symbolizing the adenosine administered for the E/c curve). 
The relative position of the simulated X-treated and X+NB co-treated E/c curves of agonist C 
demonstrates that Model 4 and Model 4-v2 are more consistent with the ex vivo data than Model 3 
(cf. Figure 1 and Figure 3), a finding that yields in silico evidence for an interaction between effects 
of FSCPX and NBTI. To gain insight into the underlying mechanism of this interaction, comparison 
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of Model 4 with Model 4-v2 provided information. Regarding the relative position of the simulated 
NB-treated and X+NB co-treated E/c curves of agonist A, Model 4 shows a greater similarity to the 
original ex vivo system than Model 4-v2 does (cf. Figure 1, Figure 3 and Figure 4). Thus, it appears 
reasonable to conclude that FSCPX pretreatment blunts only the accumulation of endogenous 
adenosine caused by NBTI. 
It is tempting to speculate about the exact molecular mechanism of FSCPX’s action other than 
irreversible antagonism on the A1 adenosine receptor. In our most recent ex vivo investigation, 
FSCPX has been assumed to blunt one (or some) enzyme(s) that participate(s) in the interstitial 
adenosine formation [14]. In this case, of course, FSCPX should inhibit the interstitial adenosine 
production in the absence of NBTI as well (i.e. upon intact nucleoside transport). An observation 
appears to contradict this conclusion, i.e. no clue of this inhibitory action is seen at the only FSCPX-
treated E/c curves of adenosine receptor agonists (in comparison with the corresponding naïve E/c 
curves) (Figure 1). However, the lack of such a clue may be because the resting level of the 
endogenous adenosine in the interstitial fluid is too low to evoke a significant negative inotropic 
effect [29]. Therefore, a decrease in the resting interstitial adenosine concentration does not uncover 
itself in the E/c curves of adenosine receptor agonists. Thus, only maneuvers producing a significant 
increase in the interstitial concentration of endogenous adenosine, such as nucleoside transport 
blockade, can reveal this putative enzyme inhibitory action of FSCPX. To clarify this issue, further 
investigations are warranted. As a first step, performing inhibitor screening assays may be useful to 
explore whether FSCPX can blunt one (or some) ectonucleotidase(s), especially ecto-apyrase CD39 
(a.k.a. lymphocyte surface protein CD39 or E-NTPDase1) and ecto-5’-nucleotidase (a.k.a. lymphocyte 
surface protein CD73), two important enzymes regarding the interstitial adenosine level in the heart 
[3]. 
An additional finding of the present investigation is that ENT1 blockade elicited by NBTI 
appears not to completely stop the inward transmembranous adenosine transport in the guinea pig 
atrium (as indicated by the comparison of Model 4 with Model 4-v1; cf. Figure 3 and Figure 4). It 
should be noted that Model 4 and Model 4-v1 contain an assumption based on the appearance of 
CPA and adenosine E/c curves generated in our ex vivo experimental setting. Namely, the only 
difference between CPA and adenosine, two full agonists for the A1 adenosine receptor, is the absence 
and presence of an inward transport, respectively. This assumption is supported by the fact that the 
synthetic CPA is relatively unaffected by adenosine-handling enzymes located mainly intracellularly, 
thus it is not transported in a significant manner, contrary to adenosine, a metabolite quickly 
transported into the cells [15]. This finding can be well explained with the existence of adenosine 
carriers other than ENT1 in the heart [30]. 
4. Materials and Methods 
4.1. Properties of the Biological System to Be Simulated 
The physiological adenosine metabolism in the heart implies a net interstitial production and 
net intracellular elimination resulting in a continuous inward transmembranous adenosine flux, 
implemented mostly (but not exclusively) via ENT1 [11,12,16-18,30]. Therefore, adenosine has shorter 
half-life than adenosine analogues more resistant to adenosine-handling enzymes, e.g. CPA [15]. 
Inhibition of ENT1 by NBTI prevents the intracellular elimination of interstitial adenosine, hence 
it elevates the interstitial level of endogenous adenosine and slows the decrease of the interstitial level 
of exogenous adenosine [18], without significantly affecting the interstitial CPA concentration [19]. 
Hence, NBTI influences the E/c curves of CPA and, especially, adenosine in a complex manner [14]. 
Based on its well-known irreversible antagonist property on the A1 adenosine receptor [7–10], 
the effect of FSCPX can be well explained in the atrial myocardium, if administered alone. Because of 
the great A1 adenosine receptor reserve related to the direct negative inotropic effect, FSCPX produces 
a dextral displacement of the E/c curve of both adenosine and CPA [10]. However, if it is used 
together with NBTI, the effect of FSCPX is no longer easy to interpret [5,6,14]. 
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4.2. Simulation of the Adenosine Homeostasis and A1 Adenosinergic Control of Contractility in the Guinea 
Pig Atrial Myocardium 
Broadly, the simulation was performed as it was described in our recent computer simulation 
study [13]. Some details were modified, as described in this subsection. To generate E/c curves 
simulating the effect of A1 adenosine receptor agonists on the contractile force of the isolated, paced 
guinea pig left atrium, the operational model of agonism was applied, both for the action of one 
agonist (Equation (1)) [21] and the co-action of two agonists (Equation (2)) [28]. The operational model 
provides a general, (fully) quantitative description of the relationship between the concentration of 
bioactive agents and the effect mediated by a receptor specific for the given agents. Moreover, this 
model contains the appropriate parameters, by means of which the effects of FSCPX (concentration 
of the operable receptors) and NBTI (parameters for two different agonists) can be considered 
[21,26,28]. 
To address the different impact of adenosine of endogenous and exogenous origins, a procedure, 
developed from RRM [19,20] and first described in [13], was applied (see: Equation (3) below). By 
means of this procedure, the neglect of one agonist from two co-acting agonists was simulated. The 
overlooked agonist concentration modelled the extra interstitial concentration of endogenous 
adenosine accumulated by NBTI, which came into being before the construction of an E/c curve with 
(exogenous) adenosine or CPA (agonists for the same receptor). 
Using different input data (Table 3) and assumptions, four models and two additional model 
variants of Model 4 were defined that resulted in six sets of E/c curves, each set containing eight 
curves, four ones belonging to agonists C and four ones belonging to agonists A (Figures 2-4). To 
characterize and illustrate the simulated E/c curves, the Hill equation (Equation (4)) was fitted to 
them. 
Adenosine, the physiological agonist for the A1 adenosine receptor, the major adenosine receptor 
type of the supraventricular myocardium [3,4], was modelled with an agonist A. Based on its location, 
two agonist A concentrations were considered, one “in the organ bath” (a “bathing medium 
concentration”), and another one “at the receptors” (a “near-receptor” concentration). Based on its 
origin, an “exogenous” (administered to generate an E/c curve) and an “endogenous” (produced in 
the atrial tissue) agonist A were distinguished. 
The inward transport of adenosine was simulated differently for the exogenous and endogenous 
agonist A. In the absence of a transport inhibitor, the concentration “in the organ bath” designated 
for the exogenous agonist A was divided by 400, when computing its effect. This maneuver simulated 
the fact that, in vivo or ex vivo, the concentration of an intensively transported agonist is lower at its 
receptors (in the interstitial fluid) than in the blood plasma or bathing medium. In the presence of a 
transport inhibitor, the concentration of the exogenous agonist A in the organ bath was not divided, 
or it was but by a number much less than 400 (6 or 14.8952), during the calculation of its effect. In 
turn, the surplus concentration of the endogenous adenosine, accumulated by a transport inhibitor, 
was considered as a cbias value of agonist A, using arbitrary values or values measured in the most 
recent ex vivo study [14], when calculating its effect (Table 3). All E/c curves generated with the 
consideration of cbias (i.e. all E/c curves reflecting the effect of a transport inhibitor) were regarded as 
“biased”. This is because it was simulated that cbias and its effect were neglected during the evaluation 
of the raw E/c data. (Indeed, this is the case during a conventional evaluation of E/c data measured 
in the presence of a transport inhibitor that accumulates an unknown amount of the endogenous 
agonist for the given receptor.) 
CPA, a synthetic agonist of the A1 adenosine receptor, was modelled with an agonist C. As CPA 
is eliminated by adenosine-handling enzymes to a much lesser extent than adenosine, the “bathing 
medium concentration” and “near-receptor concentration” of agonist C were considered to be equal. 
Accordingly, when calculated its effect, the “bathing medium concentration” of agonist C was never 
divided throughout the simulation. 
FSCPX, an irreversible A1 adenosine receptor antagonist, was modelled with an agent X. The 
effect of a pretreatment with agent X was considered with a division of the total receptor 
concentration ([R0]) by ≈5.556 (Table 3), simulating that 18% of the A1 adenosine receptors remained 
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intact (in agreement with our previous results [10]). In Model 4 and its variants, if a transport inhibitor 
was present, the agent X pretreatment was considered with a second procedure as well, by 
introducing a further cbias value (see: next paragraph and Table 3). Moreover, in Model 4-v2 (one of 
the variants), if a transport inhibitor was present, the agent X pretreatment was considered with a 
third procedure as well, through an additional division by 14.8952, when computing the “near-
receptor” concentration of agonist A (see subsection 4.6.). 
NBTI, a nucleoside transport inhibitor, was modelled by an agent NB. Its effect was taken into 
account by omitting the division of the exogenous agonist A concentration “in the organ bath” by 
400, or by dividing it using a smaller number (as anticipated above,), and, in addition, by considering 
a surplus endogenous agonist A concentration (cbias), when computing an effect. The earlier models 
contained only one cbias (Models 1-3), whereas the final one (Model 4) and its two variants possessed 
two cbias values: one for a mere NB treatment, and the other one for an X+NB co-treatment. In Models 
1 and 2, cbias was an arbitrary value, while in Models 3 and 4, cbias values equaled the surplus interstitial 
adenosine concentrations determined in the most recent ex vivo study [14] (Table 3). As mentioned 
at the end of the previous paragraph, in Model 4 and its variants, an interaction between agent X 
pretreatment and agent NB treatment was also taken into account. 
Effect values of the simulated E/c curves were plotted against the “bathing medium 
concentrations” of the given exogenous agonist, as usually these concentrations are only known 
during the in vivo and ex vivo experiments. 
Table 3. Parameters of the operational model of agonism defining four in silico models. 
 Model 1 Model 2 Model 3 Model 4 
Em 100 99 90 
nop 75 
[R0] 
10-10  (Co) 
1.8∙10-11  (X) 
K 3∙10-5 
KE 10-13 
cbias 
2.5∙10-6 
(NB and X+NB) 
1.002∙10-7 
(NB and X+NB) 
1.002∙10-7 (NB) 
6.727∙10-9 (X+NB) 
Co: no simulated (pre)treatment; X: simulated pretreatment with agent X; NB: simulated treatment 
with agent NB; X+NB: simulated pretreatment with agent X followed by a treatment with agent 
NB (briefly, X+NB co-treatment). For an explanation of abbreviations in the first column, see 
Equation (1) and (2) below. 
4.3. Construction of Simple E/c Curves (Expressing the Action of One Agonist in a Standard Way) 
Effect values evoked by one agonist (C or A) were determined in terms of the operational model 
of agonism using the following equation (equivalent to Equation (10) in [21]): 
  opopopop
opop
nnnn
E
nn
m
cRcKK
cR
EE



][
][
0
0
, 
(1) 
where E: the effect value; Em: the upper asymptote of the signal amplification function of the system; 
[R0]: the total concentration of the operable receptors (defining a naïve receptor population and a 
reduced one); c: the “near-receptor” concentration of the (exogenous) agonist C or A (computed from 
the agonist concentration “in the organ bath”); K: the equilibrium dissociation constant of the agonist-
receptor complex (an inverse measure of agonist affinity); KE: an inverse measure of agonist efficacy; 
nop: the operational slope factor. 
The so-called “organ bath” concentrations of agonists C and A ranged from 10−10 to 10−2.5 
(≈3.1623∙10−3) mol/L. The “near-receptor” concentrations (c values for Equation (1)) were calculated 
according to the nature of the simulated agonist and treatment. To ensure the best comparability to 
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Fig. 1 (showing ex vivo results from [14]), concentrations depicted in Figures 2-4 for agonists C and 
A ranged between 10−10 to 10−4 and 10−9 to 10−2.5 mol/L, respectively. 
Atria without and with an FSCPX pretreatment were simulated using [R0] equaling 10−10 and 
1.8∙10−11, respectively. These settings agree with our previous ex vivo result, i.e. approximately 10-
20% of the original A1 adenosine receptors remained operable after a 45-min-long pretreatment with 
10 µmol/L FSCPX (followed by a 75-min washout period) in the guinea pig atrium [10]. Effect values 
calculated with Equation (1) were plotted against the organ bath concentrations of the given agonist. 
4.4. Construction of Complex E/c Curves (Representing the Co-Action of Two Agonists with the Neglect of 
One of Them) 
Effect values elicited by a surplus concentration of the endogenous agonist A produced by agent 
NB (cbias) together with increasing concentrations of the exogenous agonist C or A (ctest) were 
computed in two steps. First, intermediate effect values were generated by means of the following 
equation (equivalent with Equation (7) in [28]): 
 
    opop
op
n
testbiasbiasbiastesttest
n
testbiasbiastestbiastest
n
testbiasbiasbiastesttest
m
KcKcKcKKKc
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EE





, 
(2) 
where E: the intermediate (still “unbiased”) effect; Em: the upper asymptote of the signal amplification 
function of the system; cbias: the surplus (near-receptor) concentration of the endogenous agonist A; 
ctest: the near-receptor concentration of the exogenous agonist C or A (computed from the agonist 
concentration in the organ bath); Kbias and Ktest: K values (see: Equation (1)) for the agonist providing 
cbias and ctest, respectively; τbias and τtest: [R0]/KEbias and [R0]/KEtest, respectively, where KEbias and KEtest are 
KE values (see: Equation (1)) for the agonist supplying cbias and ctest, respectively. 
Subsequently, the intermediate effect values were transformed (“biased”) using the following 
relationship (equivalent to Equation (5) in [19], and identical with Equation (5) in [20]): 
 
biasE
E
E
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100
100100
100'
 
(3) 
where E’: the final (“biased”) effect value; E: the intermediate effect value provided by Equation (2); 
Ebias: the effect elicited by cbias (computed with Equation (2) by setting ctest at zero, with other 
parameters being the same as for the corresponding E). 
The biasing transformation by means of Equation (3) simulated the neglect of cbias and its effect 
(Ebias) during the evaluation. Upon in vivo and ex vivo experiments, of course, an E/c curve, which is 
generated in the presence of a cbias, would possess unbiased effect values and reflect the relationship 
between the cbias+ctest concentrations and the unbiased effect values (as indicated by Equation (2)), if 
it were evaluated properly (tailored to the situation and not a standard way). However, cbias and Ebias 
are typically unknown (or ignored). Final effect values yielded by Equation (3) were plotted versus 
the organ bath concentrations of the agonist providing ctest. 
4.5. Characterization of the Simulated E/c Curves 
All E/c curves were fitted to the Hill equation (used in the following form that is identical to 
Equation (10) in [31]): 
)log(log
max
50101
cECn
E
E


, 
(4) 
where E: the effect; Emax: the maximal effect achievable with the given agonist in the given system; 
EC50: the agonist concentration in the organ bath that produces half-maximal effect; n: the Hill slope 
factor; c: the agonist concentration in the organ bath. 
Use of the bathing medium (rather than near-receptor) concentrations for Equation (4) agrees 
with the curve fitting practice of in vivo and ex vivo experiments (where near-receptor concentrations 
are usually unknown). 
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4.6. Evolution of the in silico Models 
The present in silico investigation started from the initial model of our recent computer 
simulation study [13]. The model parameters were being changed to achieve the greatest similarity 
to eight E/c curves that were selected from our recent ex vivo investigation [14] (and are presented 
herein in Fig. 1). This procedure yielded four models (Models 1-4, see Table 3) and two variants of 
the last model (Models 4-v1 and 4-v2). 
In all models, agonists C and A shared the same properties, except for the inward 
transmembranous transport, which was characteristic only to agonist A. 
In Model 1, the simplest model exhibiting some similarities with the original ex vivo E/c curves 
to be modelled [14], agent NB was supposed to totally stop the transport of agonist A (i.e., division 
of the organ bath concentration of agonist A by 400 was omitted to receive the near-receptor 
concentration during the calculation of effect values for the NB-treated and X+NB co-treated E/c 
curves of agonist A). The endogenous and exogenous adenosine were handled totally separately (for 
all models, excepting Model 4-v2, see below). In Model 1, only one (arbitrary) cbias value was used, so 
no interaction was assumed between the effects of agent X and agent NB (Table 3). 
Model 2 stemmed from Model 1 through one modification, i.e. Em value was decreased from 100 
to 99 (Table 3). 
Model 3 derived from Model 1 (or, equivalently, from Model 2) via three modifications. First, Em 
was set to 90. Second, to consider the effect of agent NB (solely or along with agent X), cbias was fixed 
at a constant value, namely cx in the case of the sole NBTI treatment from [14] (i.e. the CPA 
concentration equieffective with the surplus interstitial concentration of endogenous adenosine 
produced by NBTI treatment without a previous FSCPX pretreatment). With the use of only one cbias, 
no interaction was considered between effects of agents X and NB (Table 3). Third, in Model 3, it was 
hypothesized that agent NB only slowed (and not stopped) the agonist A transport. Accordingly, the 
organ bath concentration of agonist A was divided by 6 to get the near-receptor concentration, when 
computing effect values for the NB-treated and X+NB co-treated E/c curves of agonist A. 
Into Model 4, both cx values of [14] were introduced as cbias values, i.e. CPA concentrations 
equieffective with the extra interstitial concentration of endogenous adenosine caused by NBTI 
without and with an FSCPX pretreatment. The newly introduced cbias was used to define the surplus 
endogenous agonist A concentration for the X+NB co-treated E/c curves. Use of two cbias values 
implied an interaction between the effects of agents X and NB (Table 3). 
Model 4-v1, a variant of Model 4, differed from Model 4 in that no agonist A transport was 
supposed in it under the effect of agent NB (just like in Models 1 and 2). So, the effect values of the 
NB-treated as well as X+NB co-treated E/c curves were computed from the organ bath concentrations 
of agonist A (of course, the NB treatment and X+NB co-treatment were distinguished by using 
different cbias values, as described for Model 4). 
In Model 4-v2, the other variant of Model 4, agent X was supposed to influence the action of 
agent NB on the level of the exogenous agonist A as well (and not only on the level of the endogenous 
one). This unique feature of Model 4-v2, the only difference between Models 4-v2 and Model 4, 
exhibited a previous hypothesis that emerged in [13], i.e. FSCPX exerts its effect via modifying ENT1, 
the target of NBTI. The extent of the influence of agent X on the concentration of exogenous agonist 
A was defined (somewhat arbitrarily) as follows: when calculating the effect values, the near-receptor 
concentrations for the X+NB co-treated E/c curve of agonist A were computed through dividing the 
corresponding near-receptor concentrations for the solely NB treated E/c curve of agonist A by 
14.8952. This value is the ratio of the two cx values from [14] (cx measured during the mere NBTI 
treatment per cx determined during the FSCPX+NBTI co-treatment). 
4.7. Computer Simulation and Data Analysis 
The agonist concentration (c) and EC50 were expressed as common logarithms in Equation (4), 
because Equation (4) was used for curve fitting. Effect values of Equations (1), (2) and (3) as well as 
Ebias in Equation (3) were computed with Microsoft Excel 2016 (Microsoft Co., Redmond, WA, USA). 
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For curve plotting and fitting, GraphPad Prism 8.1.1 for Windows (GraphPad Software Inc., La Jolla, 
CA, USA) was used. 
5. Conclusions 
Our goal was to perform an in silico investigation regarding the background of a paradoxical 
phenomenon, first described in [5], sc. the irreversible A1 adenosine receptor antagonist FSCPX 
apparently increases the maximal response to adenosine in the presence of NBTI. The present study 
used an improved approach for computer simulation (modelling the adenosine homeostasis and A1 
adenosinergic control of contractility in the isolated, paced guinea pig left atrium) by addressing the 
issue of Em parameter of the operational model of agonism. Taking outcomes of the current in silico 
study together with our previous in silico and ex vivo results, we have concluded that the above-
mentioned paradoxical phenomenon can be ascribed to two independent, simultaneous and additive 
factors. One is the interesting phenomenon that forms the basis of RRM [19], i.e. interstitial 
accumulation of the endogenous and exogenous adenosine exerts the opposite effect on the E/c curve 
of adenosine in our experimental arrangement (as described in [5]). The other factor underlying the 
paradoxical phenomenon investigated herein is an interference between effects of two adenosine 
analogues, FSCPX and NBTI, in our experimental setting that was first suggested in [13] and was first 
evidenced (ex vivo) in [14]. Herein, we have provided in silico evidence for this interference, 
proposing that FSCPX, in addition to antagonizing the A1 adenosine receptor, blunts the interstitial 
accumulation of endogenous (but not exogenous) adenosine produced by NBTI. 
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